L-Annamycin for Injection in Combination With Cytarabine Injection as Second Line Therapy for Remission Induction in Adult Subjects With Refractory/Relapsed AML
Study sponsor: Moleculin Biotech, Inc. · MBRX
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2029-08Estimated
Enrollment · participants312Estimated
Source updated2026-08-05Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.